With a balanced risk/reward outlook and a 12-month price target of $277.95, we recommend holding as we monitor Lululemon's ...

He also noted raised outlooks in emerging markets, especially Africa, and described CoreSite as experiencing "exceptional performance" with increased 2025 expectations after the DE1 facility ...

Q2 2025 Management View CEO Zvi Alon stated that Tigo achieved its "sixth increase in sequential quarterly revenue growth, growing 27.7% sequentially and 89.4% on a year-over-year basis." He reported ...

Apple, Microsoft, Amazon and Facebook parent Meta Platforms, four of the "Magnificent Seven," whose stocks heavily influence ...

Shipowners grapple with OPEC+ supply increases, tensions in the Middle East, and rising numbers of newbuildings.

Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

The upgrade for emerging markets reflects a more optimistic outlook globally by the Fund, which nudged global GDP growth ...

Schneider adds that investors seem optimistic about American Tower due to stronger domestic organic growth heading into ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...

Analysts William Tng and Tan Jie Hui believe Venture’s shares could find “support” at their FY2025 book value per share ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...